δ-Opioid receptor agonists inhibit migraine-related hyperalgesia, aversive state and cortical spreading depression in mice

British Journal of Pharmacology

Volumn 171, Issue 9, 2014, Pages 2375-2384

  Pradhan, Amynah A ^a,b,c,d   Smith, Monique L ^a,b,c   Zyuzin, Jekaterina ^b   Charles, Andrew ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

aura; chronic migraine; headache; hyperalgesia; negative affect; nitroglycerin

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; 9 (8 AZABICYCLO[3.2.1]OCT 3 YLIDENE) 9H XANTHENE 3 CARBOXYLIC ACID DIETHYLAMIDE; ARM 390; DELTA OPIATE RECEPTOR AGONIST; GLYCERYL TRINITRATE; JNJ 20788560; N,N DIETHYL 4 (PHENYL PIPERIDIN 4 YLIDENEMETHYL) BENZAMIDE; SUMATRIPTAN; UNCLASSIFIED DRUG; 4-(ALPHA-(4-ALLYL-2,5-DIMETHYL-1-PIPERAZINYL)-3-METHOXYBENZYL)-N,N-DIETHYLBENZAMIDE; BENZAMIDE DERIVATIVE; DELTA OPIATE RECEPTOR; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVERSIVE BEHAVIOR; CONDITIONED PLACE PREFERENCE TEST; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; FEMALE; HEAT SENSITIVITY; HYPERALGESIA; MALE; MECHANICAL STIMULATION; MIGRAINE; MIGRAINE AURA; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; SPREADING CORTICAL DEPRESSION; AGONISTS; ANIMAL; AVOIDANCE BEHAVIOR; C57BL MOUSE; DRUG EFFECTS; KNOCKOUT MOUSE; MIGRAINE DISORDERS; PATHOPHYSIOLOGY; PHYSIOLOGY; TOXICITY;

ANIMALS; AVOIDANCE LEARNING; BENZAMIDES; CORTICAL SPREADING DEPRESSION; FEMALE; HYPERALGESIA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIGRAINE DISORDERS; NITROGLYCERIN; PIPERAZINES; RECEPTORS, OPIOID, DELTA;

EID: 84898617979     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12591     Document Type: Article

References (60)

1. Afridi SK, Matharu MS, Lee L, Kaube H, Friston KJ, Frackowiak RS, et al. (2005). A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain 128 (Pt 4): 932-939. (Pubitemid 40516929)
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013) the Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
3. Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA, (2006). Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 59: 652-661.
4. Bates EA, Nikai T, Brennan KC, Fu YH, Charles AC, Basbaum AI, et al. (2010). Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice. Cephalalgia 30: 170-178.
5. Beaudry H, Proteau-Gagne A, Li S, Dory Y, Chavkin C, Gendron L, (2009). Differential noxious and motor tolerance of chronic delta opioid receptor agonists in rodents. Neuroscience 161: 381-391.
6. Bespalov AY, Tokarz ME, Bowen SE, Balster RL, Beardsley PM, (1999). Effects of test conditions on the outcome of place conditioning with morphine and naltrexone in mice. Psychopharmacology (Berl) 141: 118-122. (Pubitemid 29200162)
7. Bigal ME, Lipton RB, (2008). Excessive acute migraine medication use and migraine progression. Neurology 71: 1821-1828.
8. Bigal ME, Lipton RB, (2009). Excessive opioid use and the development of chronic migraine. Pain 142: 179-182.
9. Bigal ME, Serrano D, Reed M, Lipton RB, (2008). Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 71: 559-566.
10. Bogdanov VB, Multon S, Chauvel V, Bogdanova OV, Prodanov D, Makarchuk MY, et al. (2011). Migraine preventive drugs differentially affect cortical spreading depression in rat. Neurobiol Dis 41: 430-435.
11. Brandt MR, Furness MS, Rice KC, Fischer BD, Negus SS, (2001). Studies of tolerance and dependence with the delta-opioid agonist SNC80 in rhesus monkeys responding under a schedule of food presentation. J Pharmacol Exp Ther 299: 629-637. (Pubitemid 32979676)
12. Brennan KC, Beltran-Parrazal L, Lopez-Valdes HE, Theriot J, Toga AW, Charles AC, (2007a). Distinct vascular conduction with cortical spreading depression. J Neurophysiol 97: 4143-4151. (Pubitemid 47080646)
13. Brennan KC, Romero RM, Lopez Valdes HE, Arnold AP, Charles AC, (2007b). Reduced threshold for cortical spreading depression in female mice. Ann Neurol 61: 603-606. (Pubitemid 47068143)
14. Brennan KC, Bates EA, Shapiro RE, Zyuzin J, Hallows WC, Huang Y, et al. (2013). Casein kinase idelta mutations in familial migraine and advanced sleep phase. Sci Transl Med 5: 183ra156.
15. Breslau N, Merikangas K, Bowden CL, (1994). Comorbidity of migraine and major affective disorders. Neurology 44 (10 Suppl. 7): S17-S22.
16. Cahill CM, Morinville A, Hoffert C, O'Donnell D, Beaudet A, (2003). Up-regulation and trafficking of delta opioid receptor in a model of chronic inflammation: implications for pain control. Pain 101: 199-208. (Pubitemid 36044668)
17. Chang JC, Shook LL, Biag J, Nguyen EN, Toga AW, Charles AC, et al. (2010). Biphasic direct current shift, haemoglobin desaturation and neurovascular uncoupling in cortical spreading depression. Brain 133 (Pt 4): 996-1012.
18. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL, (1994). Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53: 55-63. (Pubitemid 24238751)
19. Charles A, (2013). Migraine: a brain state. Curr Opin Neurol 26: 235-239.
20. Christiansen I, Thomsen LL, Daugaard D, Ulrich V, Olesen J, (1999). Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. Cephalalgia 19: 660-667. (Pubitemid 29465917)
21. Codd EE, Carson JR, Colburn RW, Stone DJ, Van Besien CR, Zhang SP, et al. (2009). JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3- carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependence. J Pharmacol Exp Ther 329: 241-251.
22. Do Carmo GP, Folk JE, Rice KC, Chartoff E, Carlezon WA Jr, Negus SS, (2009) the selective non-peptidic delta opioid agonist SNC80 does not facilitate intracranial self-stimulation in rats. Eur J Pharmacol 604: 58-65.
23. Dockstader CL, van der Kooy D, (2001). Mouse strain differences in opiate reward learning are explained by differences in anxiety, not reward or learning. J Neurosci 21: 9077-9081. (Pubitemid 33054869)
24. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. (2009). EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol 16: 968-981.
25. Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F, et al. (2000). Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25: 195-200. (Pubitemid 30394992)
26. Fraser GL, Gaudreau GA, Clarke PB, Menard DP, Perkins MN, (2000). Antihyperalgesic effects of delta opioid agonists in a rat model of chronic inflammation. Br J Pharmacol 129: 1668-1672. (Pubitemid 30219009)
27. Gallantine EL, Meert TF, (2005). A comparison of the antinociceptive and adverse effects of the mu-opioid agonist morphine and the delta-opioid agonist SNC80. Basic Clin Pharmacol Toxicol 97: 39-51. (Pubitemid 40903094)
28. Gaveriaux-Ruff C, Nozaki C, Nadal X, Hever XC, Weibel R, Matifas A, et al. (2011). Genetic ablation of delta opioid receptors in nociceptive sensory neurons increases chronic pain and abolishes opioid analgesia. Pain 125: 1238-1248.
29. Greco R, Meazza C, Mangione AS, Allena M, Bolla M, Amantea D, et al. (2011). Temporal profile of vascular changes induced by systemic nitroglycerin in the meningeal and cortical districts. Cephalalgia 31: 190-198.
30. Harris GC, Altomare K, Aston-Jones G, (2001). Preference for a cocaine-associated environment is attenuated by augmented accumbal serotonin in cocaine withdrawn rats. Psychopharmacology (Berl) 156: 14-22. (Pubitemid 32646320)
31. Hummel M, Lu P, Cummons TA, Whiteside GT, (2008) the persistence of a long-term negative affective state following the induction of either acute or chronic pain. Pain 140: 436-445.
32. Hutchinson AC, Simpson GR, Randall JF, Zhang X, Calderon SN, Rice KC, et al. (2000). Assessment of SNC 80 and naltrindole within a conditioned taste aversion design. Pharmacol Biochem Behav 66: 779-787. (Pubitemid 30639473)
33. Kabli N, Cahill CM, (2007). Anti-allodynic effects of peripheral delta opioid receptors in neuropathic pain. Pain 127: 84-93. (Pubitemid 44959432)
34. King T, Vera-Portocarrero L, Gutierrez T, Vanderah TW, Dussor G, Lai J, et al. (2009). Unmasking the tonic-aversive state in neuropathic pain. Nat Neurosci 12: 1364-1366.
35. Konig M, Zimmer AM, Steiner H, Holmes PV, Crawley JN, Brownstein MJ, et al. (1996). Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature 383: 535-538. (Pubitemid 26346181)
36. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
37. Longoni R, Cadoni C, Mulas A, Di Chiara G, Spina L, (1998). Dopamine-dependent behavioural stimulation by non-peptide delta opioids BW373U86 and SNC 80: 2. Place-preference and brain microdialysis studies in rats. Behav Pharmacol 9: 9-14. (Pubitemid 28098662)
38. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
39. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ, (1988). Anatomy of CNS opioid receptors. Trends Neurosci 11: 308-314.
40. Markovics A, Kormos V, Gaszner B, Lashgarara A, Szoke E, Sandor K, et al. (2012). Pituitary adenylate cyclase-activating polypeptide plays a key role in nitroglycerol-induced trigeminovascular activation in mice. Neurobiol Dis 45: 633-644.
41. Merikangas KR, Merikangas JR, Angst J, (1993). Headache syndromes and psychiatric disorders: association and familial transmission. J Psychiatr Res 27: 197-210. (Pubitemid 23234203)
42. Negus SS, Butelman ER, Chang KJ, DeCosta B, Winger G, Woods JH, (1994). Behavioral effects of the systemically active delta opioid agonist BW373U86 in rhesus monkeys. J Pharmacol Exp Ther 270: 1025-1034. (Pubitemid 24315216)
43. Negus SS, Gatch MB, Mello NK, Zhang X, Rice K, (1998). Behavioral effects of the delta-selective opioid agonist SNC80 and related compounds in rhesus monkeys. J Pharmacol Exp Ther 286: 362-375. (Pubitemid 28318012)
44. Oitzl MS, Koroleva VI, Bures J, (1985). D-ala2-Metenkephalinamide blocks the synaptically elicited cortical spreading depression in rats. Experientia 41: 625-627. (Pubitemid 15003171)
45. Perrine SA, Hoshaw BA, Unterwald EM, (2006). Delta opioid receptor ligands modulate anxiety-like behaviors in the rat. Br J Pharmacol 147: 864-872.
46. Petrillo P, Angelici O, Bingham S, Ficalora G, Garnier M, Zaratin PF, et al. (2003). Evidence for a selective role of the delta-opioid agonist [8R-(4bS,8aalpha,8abeta, 12bbeta)]7,10-Dimethyl-1-methoxy-11-(2-methylpropyl) oxycarbonyl 5,6,7,8,12,12b-hexahydro-(9H)-4,8-methanobenzofuro[3,2-e]pyrrolo[2, 3-g]iso quinoline hydrochloride (SB-235863) in blocking hyperalgesia associated with inflammatory and neuropathic pain responses. J Pharmacol Exp Ther 307: 1079-1089. (Pubitemid 37498200)
47. Pradhan AA, Clarke PB, (2005). Comparison between delta-opioid receptor functional response and autoradiographic labeling in rat brain and spinal cord. J Comp Neurol 481: 416-426.
48. Pradhan AA, Becker JA, Scherrer G, Tryoen-Toth P, Filliol D, Matifas A, et al. (2009). In vivo delta opioid receptor internalization controls behavioral effects of agonists. PLoS ONE 4: e5425.
49. Pradhan AA, Walwyn W, Nozaki C, Filliol D, Erbs E, Matifas A, et al. (2010). Ligand-directed trafficking of the delta-opioid receptor in vivo: two paths toward analgesic tolerance. J Neurosci 30: 16459-16468.
50. Pradhan AA, Befort K, Nozaki C, Gaveriaux-Ruff C, Kieffer BL, (2011) the delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol Sci 32: 581-590.
51. Pradhan AA, Smith ML, McGuire B, Tarash I, Evans CJ, Charles A, (2013). Characterization of a Novel Model of Chronic Migraine. Pain 155: 269-274.
52. Saitoh A, Kimura Y, Suzuki T, Kawai K, Nagase H, Kamei J, (2004). Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents. J Pharmacol Sci 95: 374-380. (Pubitemid 39037898)
53. Silberstein SD, Dodick D, Freitag F, Pearlman SH, Hahn SR, Scher AI, et al. (2007). Pharmacological approaches to managing migraine and associated comorbidities-clinical considerations for monotherapy versus polytherapy. Headache 47: 585-599. (Pubitemid 46628621)
54. Sprick U, Oitzl MS, Ornstein K, Huston JP, (1981). Spreading depression induced by microinjection of enkephalins into the hippocampus and neocortex. Brain Res 210: 243-252. (Pubitemid 11145571)
55. Stevenson GW, Folk JE, Rice KC, Negus SS, (2005). Interactions between delta and mu opioid agonists in assays of schedule-controlled responding, thermal nociception, drug self-administration, and drug versus food choice in rhesus monkeys: studies with SNC80 [(+)-4-[(alphaR)-alpha-((2S,5R)-4-allyl-2,5- dimethyl-1-piperazinyl)-3-methoxybenz yl]-N,N-diethylbenzamide] and heroin. J Pharmacol Exp Ther 314: 221-231. (Pubitemid 41058259)
56. Stewart WF, Wood C, Reed ML, Roy J, Lipton RB, (2008). Cumulative lifetime migraine incidence in women and men. Cephalalgia 28: 1170-1178.
57. Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, et al. (2007) the global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27: 193-210. (Pubitemid 46354128)
58. Tzschentke TM, (2007). Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol 12: 227-462. (Pubitemid 47196347)
59. Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB, (2010). Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia 30: 1065-1072.
60. Vierck CJ, Hansson PT, Yezierski RP, (2008). Clinical and pre-clinical pain assessment: are we measuring the same thing? Pain 135: 7-10.